Detalhe da pesquisa
1.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Clin Cancer Res
; 30(4): 729-740, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109213
2.
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
NPJ Breast Cancer
; 8(1): 128, 2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36456573
3.
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ Breast Cancer
; 7(1): 131, 2021 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611148
4.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Nat Commun
; 12(1): 6428, 2021 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34741023
5.
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
J Clin Oncol
; 38(10): 1059-1069, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32031889